Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14727.203 | 0.1059 | -0.4341 | 1.7785 | |
| HCC1569 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14727.203 | 0.1059 | -0.4341 | 1.7785 | |
| HCC1569 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14727.203 | 0.1182 | -0.3979 | 1.7785 | |
| HCC1569 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14727.203 | 0.1182 | -0.3979 | 1.7785 | |
| HCC1569 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14727.203 | 0.1300 | -0.3648 | 1.7785 | |
| HCC1569 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14727.203 | 0.1300 | -0.3648 | 1.7785 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7450.074 | 1.0001 | 1.0001 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7450.074 | 1.0001 | 1.0001 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7450.074 | 1.0220 | 1.0196 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7450.074 | 1.0220 | 1.0196 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7450.074 | 0.9320 | 0.9380 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7450.074 | 0.9320 | 0.9380 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7450.074 | 0.8770 | 0.8859 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7450.074 | 0.8770 | 0.8859 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7450.074 | 0.1145 | -0.2421 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7450.074 | 0.1145 | -0.2421 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7450.074 | 0.0208 | -0.6465 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7450.074 | 0.0208 | -0.6465 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7450.074 | 0.0129 | -0.7147 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7450.074 | 0.0129 | -0.7147 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7450.074 | 0.0122 | -0.7221 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7450.074 | 0.0122 | -0.7221 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 167 | uM | 7450.074 | 0.0099 | -0.7462 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 167 | uM | 7450.074 | 0.0099 | -0.7462 | 2.2338 | |
| HCC1806 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7451.074 | 1.0095 | 1.0087 | 2.1799 |